Focus: Regulators Enter the Drug Pricing Debate
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, pharma industry, regulation
By Anjali Shukla The Chinese authorities have come down strongly on the issue of drug costs, slashing the prices of …
MOD to ban use of Roche anti-malaria drug, Lariam, for armed forces
May 24, 2016Manufacturing and Production, Sales and Marketing anti-malaria drug, armed forces, lariam, mod
A parliamentary committee has published a new report urging the armed forces not to use anti-malaria drug, Lariam, due to …
Pfizer says EMA lifts warning on its smoking cessation drug Champix
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing Champix, EMA, Pfizer, anti-smoking, drug trial
US pharma giant Pfizer (NYSE: PFE) said the European Medicines Agency has lifted a warning on its anti-smoking drug Champix …
CSL’s flu vaccine scores FDA approval
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing CSL, FDA, Vaccine, flu, four strain, four-strain, influenza, influenza a, influenza b, seqirus
Seqirus, a division of CSL, has announced that the US Food and Drug Administration (FDA) has approved Flucelvax Quadrivalent (influenza …
Sandoz biosimilar accepted for regulatory submission by EMA
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing EMA, Sandoz, biosimilar
Sandoz, a division of Novartis, has announced that the European Medicines Agency (EMA) has accepted its marketing authorisation application for …
US FDA advisors question usefulness of Sanofi’s combination diabetes therapy
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, US FDA, diabetes, drug trial, regulation
US Food and Drug Administration staff questioned the benefits of French drugmaker Sanofi’s (Euronext: SAN) diabetes drug candidate as well …
French authorities pins blame on Bial and Biotrial for fatal drug trial
May 24, 2016Manufacturing and Production, Research and Development Bial, Biotrial, France, blame, clinical trial, death, disaster, minister for health, report
Authorities in France have criticised the pharmaceutical company and the clinical research organisation at the centre of the Rennes clinical …
Janssen’s Darzalex gets conditional European Commission approval to treat multiple myeloma
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing
Janssen said the European Commission (EC) conditionally approved its biologic Darzalex (daratumumab) to treat blood cancer. The company said Daratumumab …
Kite Pharma names Paul Jenkinson CFO
May 23, 2016Research and Development, Sales and Marketing appointment, cfo, kite pharma
Kite Pharma (Nasdaq: KITE) has appointed Paul Jenkinson its chief financial officer. Jenkinson succeeds Cynthia Butitta, who will continue in her role as …
Novartis’ heart failure drug Entresto gets top US, EU recommendation
May 23, 2016Research and Development, Sales and Marketing Ernesto, Novartis, heart failure, regulation
Swiss drugmaker Novartis (VTX: NOVN) said its heart failure drug Entresto (sacubitril/ valsartan) has secured top recommendations in the US …
China to cut prices of GSK, AstraZeneca drugs
May 23, 2016Sales and Marketing AstraZeneca, China, GSK, drug prices
Chinese health authorities have announced steps to cut the prices of three costly drugs in their latest attempt to reduce …
Weekly Movers: Valeant, Anacor, Regeneron…
May 23, 2016Manufacturing and Production, Research and Development, Sales and Marketing Acorda, Aduro Biotech, Anacor Pharma, Financial, MacroGenics, Merck, Regeneron Pharma, Valeant Pharma
The earnings season came to a close with Germany’s Merck doubling its first-quarter profits. For the week, drug trials, analyst …
Biotech firm fined $3.5 million for animal mistreatment
May 23, 2016Medical Communications, Sales and Marketing US department of agriculture, animal cruelty, animal mistreatment, antibody, santa cruz biotechnology, usda
A US-based biotechnology company has been fined $3.5 million by the US Department of Agriculture (USDA) for a case related …
Bayer offers $62 billion for Monsanto in all cash deal
May 23, 2016Research and Development, Sales and Marketing Bayer, Deals, Financial, Merger & Acquisition, monsanto
German pharma and crop sciences giant Bayer (ETR: BAYN) has made an unsolicited $62 billion all-cash offer for Monsanto Co …
Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug
May 23, 2016Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B
Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …
EMA to review Pfizer’s meningococcal vaccine
May 20, 2016Research and Development, Sales and Marketing EMA, Pfizer, meningitis, meningococcal vaccine, trumenba
Pfizer (NYSE: PFE) has announced that the European Medicines Agency has accepting the marketing authorisation application for its meningococcal group …
MSF says staff member shot dead in Central African Republic; suspends activity in the area
May 20, 2016Medical Communications Central African republic, MSF
The medical aid charity Doctors without Borders (MSF) said it is suspending activities in the Central African Republic (CAR) following an …
Nice backs Novartis’ lung cancer drug
May 20, 2016NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …
Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug
May 20, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights
Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …
UK regulators do not back Roche’s breast cancer drug
May 20, 2016Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer, recommendation
The National Institute for Health and Care Excellence (Nice) has provisionally turned down Swiss drugmaker Roche’s (VTX: ROG) breast cancer …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
